Epidemiology Profile of Stage IV Ovarian Cancer in Dharmais National Cancer Hospital: An Observational Study
Abstract
Background: Stage IV ovarian cancer showed a low 5-year survival rate, around 31%. Regrettably, the unclear symptoms and the ineffectiveness of early detection result in many patients being diagnosed with stage IV. Moreover, establishing a stage IV diagnosis is challenging and tricky. This study aims to provide a comprehensive overview of the clinical, laboratory, histopathological, and survival characteristics of stage IV ovarian cancer patients.
Method: A cross-sectional study with a descriptive observational design, 100 of 1520 subjects gathered from the Cancer Registry of Dharmais National Cancer Hospital between January 2018 and December 2022, conducted on stage IV ovarian cancer patients who were not accompanied by primary cancer at other sites.
Results: Among the 100 study subjects, 76.0% were aged 40–60 years, with a median age of 49.5 years. Most had a normal nutritional status (39.0%) or were underweight (34.0%). Comorbidities were present in 40.0% of the subjects, with hypertension being the most common (57.5%). The initial symptoms were abdominal enlargement in 74.0% of subjects, with 43.0% reporting shortness of breath. Laboratory examinations revealed that the majority had hemoglobin levels > 10 mg/dL (90.0%), serum creatinine levels < 1.2 mg/dL (90.0%), and D-Dimer levels > 2000 ng/ mL (69.0%). Histopathological analysis identified high-grade serous carcinoma (HGSC) in 24.0% and clear cell carcinoma in 19.0% of subjects. The most common metastatic sites were the pleura (44.0%), liver (41.0%), and lungs (25.0%). Around 48.0% and 41.0% had surgery only and surgery with adjuvant chemotherapy, respectively. The majority of the outcomes (91.0%) indicated that patients with stage IV ovarian cancer did not survive and the median survival among the subjects was 4 months.
Conclusion: The majority of stage IV ovarian cancer patients were aged 40–60 years, with abdominal enlargement as the initial symptoms, elevated D-Dimer levels, HGSC as the predominant histopathological type, and a high mortality rate as the outcome. Further research is recommended to explore additional variables and analyze factors contributing to mortali
Keywords
DOI: 10.33371/ijoc.v19i1.1308
Article Metrics


References
World Health Organization. Global Cancer Observatory: Indonesia Fact Sheet [Internet]. Lyon: International Agency for Research on Cancer; 2022 [cited 2024 Sept 3]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf
World Health Organization. Global Cancer Observatory: World Fact Sheet [Internet]. Lyon: International Agency for Research on Cancer; 2022 [cited 2024 Sept 3]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf
American Cancer Society. Survival Rates for Ovarian Cancer [Internet]. March 1st, 2023 [cited 2024 Sept 3]. Available from: https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html
Bannister N, Braggio J. Cancer survival in England: adult, stage at diagnosis and childhood – patients followed up to 2016 [Internet]. London: Office for National Statistics; 2017 [cited 2024 Sept 3]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/adultstageatdiagnosisandchildhoodpatientsfollowedupto2016
Badgwell D, Bast RC. Early Detection of Ovarian Cancer. Dis Markers. 2007;23(5–6):397–410.
Dilley J, Burnell M, Gentry-Maharaj A, et al. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020;158(2):316–22.
Macciò A, Madeddu C, Massa D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005 Jul 1;106(1):362–7.
Khonsa O, Nuranna L, Sutrisna B. Kesintasan Pasien Karsinoma Ovarium dan Faktor-faktor yang Mempengaruhinya di RSUPN Dr. Cipto Mangunkusumo Jakarta (Pemantauan 5 tahun). 31(2).
Rahmalia K, Sudiarta KE, Setianingsih H, Diarsvitri W. The Characteristics of Sociodemography, Histopathologic Features, Stage, and Management of Ovarian Cancer in Dr. Ramelan Navy Hospital Surabaya. Indones J Cancer. 2024 Jun 27;18(2):130–6.
National Cancer Institute. Ovary Stage Distribution of SEER Incidence Cases, 2012-2021 [Internet]. Bethesda: National Cancer Institute; 2023 [cited 2024 Sept 3]. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html?site=61&data_type=1&graph_type=4&compareBy=age_range&chk_age_range_1=1&chk_age_range_62=62&chk_age_range_122=122&chk_age_range_160=160&chk_age_range_166=166&hdn_sex=3&race=4&advopt_precision=1&hdn_view=0
Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47–47.
Liu J, Berchuck A, Backes FJ, et al. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(8):512-9.
Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol. 2009;20(1):8.
Berkowitz Z, Rim SH, Peipins LA. Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer. Cancer Epidemiol. 2011 Apr;35(2):112–9.
Bandera EV, Lee VS, Qin B, et al. Impact of body mass index on ovarian cancer survival varies by stage. Br J Cancer. 2017 Jul;117(2):282–9.
Evans WJ, Morley JE, Argilés J, et al. Cachexia: A new definition. Clin Nutr. 2008;27(6):793–9.
Gunawan Y, Winarto H. Body weight, hemoglobin, and absolute neutrophil count in patients with advanced-stage epithelial ovarian cancer who received chemotherapy: A single-center study. J Phys Conf Ser. 2017 Aug;884:012029.
Le Saux O, Taylor A, Pillas D, et al. Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France. Clin Epidemiol. 2015;431.
Tetsche MS, Dethlefsen C, Pedersen L, et al. The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study. BMC Cancer. 2008;8(1):31.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373–83.
Jiao YS, Gong TT, Wang YL, Wu QJ. Comorbidity and survival among women with ovarian cancer: evidence from prospective studies. Sci Rep. 2015;5(1):11720.
Gijsen R, Hoeymans N, Schellevis FG, et al. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 2001 Jul;54(7):661-74.
Matsuo K, Ahn EH, Prather CP, et al. Patient-Reported Symptoms and Survival in Ovarian Cancer. Int J Gynecol Cancer. 2011;21(9):1555–65.
Meena RK, Syed NA, Sheikh ZA, et al. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022;(8):e2200032.
Noviyani R, Indrayathi PA, Budiana ING, et al. Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment: In: Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development [Internet]. East Jakarta, Indonesia: SCITEPRESS - Science and Technology Publications; 2018 [cited 2024 Sep 2]. Available from: http://www.scitepress.org/DigitalLibrary/Link.aspx?doi=10.5220/0008238900330038
Lafleur J, Hefler-Frischmuth K, Grimm C, et al. Prognostic Value of Serum Creatinine Levels in Patients with Epithelial Ovarian Cancer. Anticancer Res. 2018;38(9):5127–30.
Anderson PO, Knoben JE, Troutman WG, editors. Handbook of clinical drug data. 10th ed. New York: McGraw-Hill Medical Pub. Division; 2002. 1148 p.
Sakurai M, Satoh T, Matsumoto K, et al. High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension. Int J Gynecol Cancer. 2015;25(4):593–8.
Wu J, Fu Z, Liu G, et al. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine (Baltimore). 2017;96(25):e7062.
Caine GJ, Stonelake PS, Lip GYH, Kehoe ST. The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate. Neoplasia. 2002;4(6):465–73.
Deng K, Yang C, Tan Q, et al. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol Oncol. 2018;150(3):460–5.
Winarto H, Welladatika A, Habiburrahman M, et al. Overall Survival and Related Factors of Advanced-stage Epithelial Ovarian Cancer Patients Underwent Debulking Surgery in Jakarta, Indonesia: A Single-center Experience. Open Access Maced J Med Sci. 2022;10(B):265–80.
Andreou M, Kyprianidou M, Cortas C, et al. Prognostic Factors Influencing Survival in Ovarian Cancer Patients: A 10-Year Retrospective Study. Cancers (Basel). 2023;15(24):5710.
Mizuno M, Kajiyama H, Shibata K, et al. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients. Br J Cancer. 2015;112(8):1376–83.
Marth C, Abreu MH, Andersen KK, et al. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial). Cancer. 2022;128(16):3080–9.
Urban RR, He H, Alfonso R, et al. Ovarian cancer outcomes: Predictors of early death. Gynecol Oncol. 2016;140(3):474–80.
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.